PubmedID,Title,Publication Date,Non-academic Author(s),Company Affiliation(s)
40673766,"Safety, tolerability, and pharmacokinetics of anti-SARS-CoV-2 monoclonal antibody SA55 injection in healthy participants.",2025,Xing Meng,"Clinical Research and Development Center Sinovac Biotech Co., Ltd., Beijing, China."
40673766,"Safety, tolerability, and pharmacokinetics of anti-SARS-CoV-2 monoclonal antibody SA55 injection in healthy participants.",2025,Jianhua Li,"Zhejiang Key Laboratory of Public Health Detection and Pathogenesis Research, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China."
40673766,"Safety, tolerability, and pharmacokinetics of anti-SARS-CoV-2 monoclonal antibody SA55 injection in healthy participants.",2025,Gang Zeng,"Clinical Research and Development Center Sinovac Biotech Co., Ltd., Beijing, China."
40456235,Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial.,2025,Olivier Laurent,"Prometheus Biosciences, a subsidiary of Merck & Co, Rahway, NJ, USA."
40456235,Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial.,2025,Allison Luo,"Prometheus Biosciences, a subsidiary of Merck & Co, Rahway, NJ, USA."
40456235,Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial.,2025,Jiandong Lu,"Prometheus Biosciences, a subsidiary of Merck & Co, Rahway, NJ, USA."
40456235,Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial.,2025,Deanna D Nguyen,"Prometheus Biosciences, a subsidiary of Merck & Co, Rahway, NJ, USA."
40456235,Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial.,2025,Ernesto J Muñoz-Elias,"Merck & Co, Rahway, NJ, USA."
40456235,Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial.,2025,Heather Llewellyn,"Merck & Co, Rahway, NJ, USA."
40456235,Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial.,2025,Yong Wang,"Merck & Co, Rahway, NJ, USA."
40456235,Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial.,2025,InSock Jang,"Merck & Co, Rahway, NJ, USA."
40456235,Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial.,2025,Ron Marchelletta,"Merck & Co, Rahway, NJ, USA."
40456235,Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial.,2025,Fadi Towfic,"Prometheus Biosciences, a subsidiary of Merck & Co, Rahway, NJ, USA."
40456235,Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial.,2025,Mark Yen,"Merck & Co, Rahway, NJ, USA."
40456235,Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial.,2025,Jaclyn K Anderson,"Merck & Co, Rahway, NJ, USA."
40418545,COVID-19 clinical outcomes and N-acetylcysteine (CoViNAC study): a GRADE compliant meta-analysis of randomized controlled trials with molecular docking and dynamics simulation studies with Mpro of SARS-CoV-2.,2025,Seshadri Reddy Varikasuvu,"Department of Biochemistry, All India Institute of Medical Sciences (AIIMS), Deoghar, India. lifeschemistry@live.com."
40418545,COVID-19 clinical outcomes and N-acetylcysteine (CoViNAC study): a GRADE compliant meta-analysis of randomized controlled trials with molecular docking and dynamics simulation studies with Mpro of SARS-CoV-2.,2025,Munikumar Manne,"Director of Academics and Training, Bioinformatics Division, Manna Biotech Private Limited, Hyderabad-500076, Telangana, India. mannemunikumar.bioinfo@gmail.com."
40418545,COVID-19 clinical outcomes and N-acetylcysteine (CoViNAC study): a GRADE compliant meta-analysis of randomized controlled trials with molecular docking and dynamics simulation studies with Mpro of SARS-CoV-2.,2025,Subodh Kumar,"Pharmacology, All India Institute of Medical Sciences (AIIMS), Deoghar, India. drsubodh27@gmail.com."
40418545,COVID-19 clinical outcomes and N-acetylcysteine (CoViNAC study): a GRADE compliant meta-analysis of randomized controlled trials with molecular docking and dynamics simulation studies with Mpro of SARS-CoV-2.,2025,Shiv Kumar Mudgal,"Nursing, All India Institute of Medical Sciences (AIIMS), Deoghar, India. shiv.nur@aiimsdeoghar.edu.in."
40418545,COVID-19 clinical outcomes and N-acetylcysteine (CoViNAC study): a GRADE compliant meta-analysis of randomized controlled trials with molecular docking and dynamics simulation studies with Mpro of SARS-CoV-2.,2025,Vikash Raj,"Orthopaedics, All India Institute of Medical Sciences (AIIMS), Deoghar, India. drvikashraj@gmail.com."
40418545,COVID-19 clinical outcomes and N-acetylcysteine (CoViNAC study): a GRADE compliant meta-analysis of randomized controlled trials with molecular docking and dynamics simulation studies with Mpro of SARS-CoV-2.,2025,Saurabh Varshney,"Otorhinolaryngology, All India Institute of Medical Sciences (AIIMS), Deoghar, India. drsaurabh68@gmail.com."
40418545,COVID-19 clinical outcomes and N-acetylcysteine (CoViNAC study): a GRADE compliant meta-analysis of randomized controlled trials with molecular docking and dynamics simulation studies with Mpro of SARS-CoV-2.,2025,Pratima Gupta,"Microbiology, All India Institute of Medical Sciences (AIIMS), Deoghar, India. drpratima68@gmail.com."
40418545,COVID-19 clinical outcomes and N-acetylcysteine (CoViNAC study): a GRADE compliant meta-analysis of randomized controlled trials with molecular docking and dynamics simulation studies with Mpro of SARS-CoV-2.,2025,Vanita Lal,"Department of Biochemistry, All India Institute of Medical Sciences (AIIMS), Deoghar, India. laldasvanita@gmail.com."
40418545,COVID-19 clinical outcomes and N-acetylcysteine (CoViNAC study): a GRADE compliant meta-analysis of randomized controlled trials with molecular docking and dynamics simulation studies with Mpro of SARS-CoV-2.,2025,Harminder Singh,"Pharmacology, All India Institute of Medical Sciences (AIIMS), Deoghar, India. harminder.pharmacology@aiimsdeoghar.edu.in."
40418545,COVID-19 clinical outcomes and N-acetylcysteine (CoViNAC study): a GRADE compliant meta-analysis of randomized controlled trials with molecular docking and dynamics simulation studies with Mpro of SARS-CoV-2.,2025,Mona Lisa,"Department of Pathology, All India Institute of Medical Sciences (AIIMS), Deoghar, India. monaloud@gmail.com."
40355744,Nicotinamide modulates gut microbial metabolic potential and accelerates recovery in mild-to-moderate COVID-19.,2025,Oliver Harzer,"Bioscientia Healthcare GmbH, Ingelheim, Germany."
40355744,Nicotinamide modulates gut microbial metabolic potential and accelerates recovery in mild-to-moderate COVID-19.,2025,Belén Millet Pascual-Leone,"Department of Infectious Diseases, Respiratory Medicine and Critical Care, Charité-Universitätsmedizin Berlin, a corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany."
40355744,Nicotinamide modulates gut microbial metabolic potential and accelerates recovery in mild-to-moderate COVID-19.,2025,Regina Hollweck,"Novustat GmbH, Wollerau, Switzerland."
40346656,The TyphiNET data visualisation dashboard: unlocking Salmonella Typhi genomics data to support public health.,2025,Zoe A Dyson,"Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK. zoe.dyson@lshtm.ac.uk."
40269252,"{'sup': '®', '#text': 'Effect of heterologous intranasal iNCOVACC vaccination as a booster to two-dose intramuscular Covid-19 vaccination series: a randomized phase 3 clinical trial.'}",2025,Chandramani Singh,"All India Institute of Medical Sciences, Patna, Bihar, India."
40269252,"{'sup': '®', '#text': 'Effect of heterologous intranasal iNCOVACC vaccination as a booster to two-dose intramuscular Covid-19 vaccination series: a randomized phase 3 clinical trial.'}",2025,Sanjay K Rai,"All India Institute of Medical Sciences, New Delhi, India."
40269252,"{'sup': '®', '#text': 'Effect of heterologous intranasal iNCOVACC vaccination as a booster to two-dose intramuscular Covid-19 vaccination series: a randomized phase 3 clinical trial.'}",2025,Krishna Mohan Vadrevu,"Bharat Biotech International Limited, Hyderabad, India. kmohan@bharatbiotech.com."
40191455,Rerouting therapeutic peptides and unlocking their potential against SARS-CoV2.,2025,Saharuddin Bin Mohammed,"Institute of Biological Sciences, Faculty of Science, Universiti Malaya, 50603 Kuala Lumpur, Malaysia."
40138386,Selective C-reactive protein apheresis in acute myocardial infarction: rationale and design of a prospective international randomized controlled trial.,2025,Stephan Mattecka,"Capture Biotech GmbH, Berlin."
40138386,Selective C-reactive protein apheresis in acute myocardial infarction: rationale and design of a prospective international randomized controlled trial.,2025,Ahmed Sheriff,"Capture Biotech GmbH, Berlin."
40118493,Readability and complexity of written information presented to hospitalised patients for trial consent during the COVID-19 pandemic in the UK: a retrospective document analysis.,2025,Nick A Maskell,"Academic Respiratory Unit, Department of Clinical Sciences, Bristol University, Bristol, UK."
40116355,"Pharmacokinetics and Safety Profile of SNS812, a First in Human Fully Modified siRNA Targeting Wide-Spectrum SARS-CoV-2, in Healthy Subjects.",2025,Yi-Chung Chang,"Oneness Biotech Company Limited, Taipei, Taiwan."
40116355,"Pharmacokinetics and Safety Profile of SNS812, a First in Human Fully Modified siRNA Targeting Wide-Spectrum SARS-CoV-2, in Healthy Subjects.",2025,Yi-Fen Chen,"Oneness Biotech Company Limited, Taipei, Taiwan."
40116355,"Pharmacokinetics and Safety Profile of SNS812, a First in Human Fully Modified siRNA Targeting Wide-Spectrum SARS-CoV-2, in Healthy Subjects.",2025,Chi-Fan Yang,"Microbio (Shanghai) Biotech Company, Shanghai, China."
40116355,"Pharmacokinetics and Safety Profile of SNS812, a First in Human Fully Modified siRNA Targeting Wide-Spectrum SARS-CoV-2, in Healthy Subjects.",2025,Hui-Ju Ho,"Oneness Biotech Company Limited, Taipei, Taiwan."
40116355,"Pharmacokinetics and Safety Profile of SNS812, a First in Human Fully Modified siRNA Targeting Wide-Spectrum SARS-CoV-2, in Healthy Subjects.",2025,Jen Fu Yang,"Oneness Biotech Company Limited, Taipei, Taiwan."
40116355,"Pharmacokinetics and Safety Profile of SNS812, a First in Human Fully Modified siRNA Targeting Wide-Spectrum SARS-CoV-2, in Healthy Subjects.",2025,Yuan-Lin Chou,"Microbio (Shanghai) Biotech Company, Shanghai, China."
40116355,"Pharmacokinetics and Safety Profile of SNS812, a First in Human Fully Modified siRNA Targeting Wide-Spectrum SARS-CoV-2, in Healthy Subjects.",2025,Ching-Wen Lin,"Oneness Biotech Company Limited, Taipei, Taiwan."
40116355,"Pharmacokinetics and Safety Profile of SNS812, a First in Human Fully Modified siRNA Targeting Wide-Spectrum SARS-CoV-2, in Healthy Subjects.",2025,Pan-Chyr Yang,"Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan."
40064458,Nonclinical safety and biodistribution evaluation of HC009 mRNA vaccine against COVID-19 in rat.,2025,Juan Liu,"Nucleic Acid Medicine Innovation Center, Zhejiang Haichang Biotech Co., Ltd., Hangzhou, Zhejiang 310020, China. Electronic address: liuj@zhejianghaichang.com."
40064458,Nonclinical safety and biodistribution evaluation of HC009 mRNA vaccine against COVID-19 in rat.,2025,Xicheng Chen,"Nucleic Acid Medicine Innovation Center, Zhejiang Haichang Biotech Co., Ltd., Hangzhou, Zhejiang 310020, China."
40064458,Nonclinical safety and biodistribution evaluation of HC009 mRNA vaccine against COVID-19 in rat.,2025,Chuanqian Chen,"Nucleic Acid Medicine Innovation Center, Zhejiang Haichang Biotech Co., Ltd., Hangzhou, Zhejiang 310020, China."
40064458,Nonclinical safety and biodistribution evaluation of HC009 mRNA vaccine against COVID-19 in rat.,2025,Jie Wu,"Nucleic Acid Medicine Innovation Center, Zhejiang Haichang Biotech Co., Ltd., Hangzhou, Zhejiang 310020, China."
40064458,Nonclinical safety and biodistribution evaluation of HC009 mRNA vaccine against COVID-19 in rat.,2025,Fengyang Xie,"Nucleic Acid Medicine Innovation Center, Zhejiang Haichang Biotech Co., Ltd., Hangzhou, Zhejiang 310020, China."
40064458,Nonclinical safety and biodistribution evaluation of HC009 mRNA vaccine against COVID-19 in rat.,2025,Jing Li,"Nucleic Acid Medicine Innovation Center, Zhejiang Haichang Biotech Co., Ltd., Hangzhou, Zhejiang 310020, China."
40064458,Nonclinical safety and biodistribution evaluation of HC009 mRNA vaccine against COVID-19 in rat.,2025,Huafeng Han,"Nucleic Acid Medicine Innovation Center, Zhejiang Haichang Biotech Co., Ltd., Hangzhou, Zhejiang 310020, China."
40064458,Nonclinical safety and biodistribution evaluation of HC009 mRNA vaccine against COVID-19 in rat.,2025,Yingying Zhao,"Nucleic Acid Medicine Innovation Center, Zhejiang Haichang Biotech Co., Ltd., Hangzhou, Zhejiang 310020, China."
40064458,Nonclinical safety and biodistribution evaluation of HC009 mRNA vaccine against COVID-19 in rat.,2025,Yongsheng Yang,"Nucleic Acid Medicine Innovation Center, Zhejiang Haichang Biotech Co., Ltd., Hangzhou, Zhejiang 310020, China. Electronic address: yongsheng.yang@thewogroup.com."
40045918,"Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials.",2025,Akimichi Morita,"Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan."
40045918,"Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials.",2025,Matthew J Colombo,"Bristol Myers Squibb, Princeton, New Jersey, USA."
40045918,"Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials.",2025,Julie Scotto,"Bristol Myers Squibb, Princeton, New Jersey, USA."
40045918,"Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials.",2025,John Vaile,"Bristol Myers Squibb, Princeton, New Jersey, USA."
40045918,"Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials.",2025,Joe Zhuo,"Bristol Myers Squibb, Princeton, New Jersey, USA."
40045918,"Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials.",2025,Eleni Vritzali,"Bristol Myers Squibb, Princeton, New Jersey, USA."
40045918,"Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials.",2025,Victoria Berger,"Bristol Myers Squibb, Princeton, New Jersey, USA."
40045918,"Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials.",2025,Georgene Schroeder,"Bristol Myers Squibb, Princeton, New Jersey, USA."
40045918,"Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials.",2025,Subhashis Banerjee,"Bristol Myers Squibb, Princeton, New Jersey, USA."
40015292,"Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial.",2025,Steven Thomas,"Biometrics, BioPharmaceuticals Research & Development, AstraZeneca, Gaithersburg, MD, USA; Vaccines & Immune Therapies, BioPharmaceuticals Research & Development, AstraZeneca, Gaithersburg, MD, USA; Chiesi USA, Cary, NC, USA."
40015292,"Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial.",2025,Anastasia A Aksyuk,"Vaccines & Immune Therapies, BioPharmaceuticals Research & Development, AstraZeneca, Gaithersburg, MD, USA."
40015292,"Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial.",2025,Lindsay E Clegg,"Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals Research & Development, AstraZeneca, Gaithersburg, MD, USA."
40015292,"Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial.",2025,Alexander Currie,"Vaccines & Immune Therapies, BioPharmaceuticals Research & Development, AstraZeneca, Cambridge, UK."
40015292,"Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial.",2025,Haitao Yang,"Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals Research & Development, AstraZeneca, Gaithersburg, MD, USA."
40015292,"Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial.",2025,Karin Flyrin,"Vaccines & Immune Therapies, BioPharmaceuticals Research & Development, AstraZeneca, Mölndal, Sweden."
40015292,"Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial.",2025,Michael Gibbs,"Vaccines & Immune Therapies, BioPharmaceuticals Research & Development, AstraZeneca, Cambridge, UK."
40015292,"Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial.",2025,Manish Shroff,"Patient Safety, Chief Medical Office, Research & Development, AstraZeneca, Waltham, MA, USA."
40015292,"Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial.",2025,John L Perez,"Vaccines & Immune Therapies, BioPharmaceuticals Research & Development, AstraZeneca, Gaithersburg, MD, USA."
40015292,"Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial.",2025,Lee-Jah Chang,"Vaccines & Immune Therapies, BioPharmaceuticals Research & Development, AstraZeneca, Gaithersburg, MD, USA."
40015292,"Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial.",2025,Taylor S Cohen,"Vaccines & Immune Therapies, BioPharmaceuticals Research & Development, AstraZeneca, Gaithersburg, MD, USA. Electronic address: taylor.cohen@astrazeneca.com."
39911577,"CoviWall, a whole-virion-inactivated B.1.617.2 vaccine candidate, induces potent humoral and Th1 cell response in mice and protects against B.1.617.2 strain challenge in Syrian hamsters.",2024,Jyotsna Dandotiya,"Immuno-biology Lab, Centre for Immunobiology and Immunotherapy, Translational Health Science and Technology Institute, Near Capital Region (NCR)-Biotech Science Cluster, Faridabad, Haryana, India."
39911577,"CoviWall, a whole-virion-inactivated B.1.617.2 vaccine candidate, induces potent humoral and Th1 cell response in mice and protects against B.1.617.2 strain challenge in Syrian hamsters.",2024,Neeta Adhikari,"Immuno-biology Lab, Centre for Immunobiology and Immunotherapy, Translational Health Science and Technology Institute, Near Capital Region (NCR)-Biotech Science Cluster, Faridabad, Haryana, India."
39911577,"CoviWall, a whole-virion-inactivated B.1.617.2 vaccine candidate, induces potent humoral and Th1 cell response in mice and protects against B.1.617.2 strain challenge in Syrian hamsters.",2024,Manas Ranjan Tripathy,"Immuno-biology Lab, Centre for Immunobiology and Immunotherapy, Translational Health Science and Technology Institute, Near Capital Region (NCR)-Biotech Science Cluster, Faridabad, Haryana, India."
39911577,"CoviWall, a whole-virion-inactivated B.1.617.2 vaccine candidate, induces potent humoral and Th1 cell response in mice and protects against B.1.617.2 strain challenge in Syrian hamsters.",2024,Dibya Ranjan Pati,"Translational Health Science & Technology Institute (THSTI), NCR-Biotech Science Cluster, Faridabad, Haryana, India."
39911577,"CoviWall, a whole-virion-inactivated B.1.617.2 vaccine candidate, induces potent humoral and Th1 cell response in mice and protects against B.1.617.2 strain challenge in Syrian hamsters.",2024,Vibhu Kanchan,"Translational Health Science & Technology Institute (THSTI), NCR-Biotech Science Cluster, Faridabad, Haryana, India."
39911577,"CoviWall, a whole-virion-inactivated B.1.617.2 vaccine candidate, induces potent humoral and Th1 cell response in mice and protects against B.1.617.2 strain challenge in Syrian hamsters.",2024,Varsha S Prasad,"Translational Health Science & Technology Institute (THSTI), NCR-Biotech Science Cluster, Faridabad, Haryana, India."
39911577,"CoviWall, a whole-virion-inactivated B.1.617.2 vaccine candidate, induces potent humoral and Th1 cell response in mice and protects against B.1.617.2 strain challenge in Syrian hamsters.",2024,Jitendra Kumar,"Translational Health Science & Technology Institute (THSTI), NCR-Biotech Science Cluster, Faridabad, Haryana, India."
39911577,"CoviWall, a whole-virion-inactivated B.1.617.2 vaccine candidate, induces potent humoral and Th1 cell response in mice and protects against B.1.617.2 strain challenge in Syrian hamsters.",2024,Nitesh K Senapati,"Translational Health Science & Technology Institute (THSTI), NCR-Biotech Science Cluster, Faridabad, Haryana, India."
39911577,"CoviWall, a whole-virion-inactivated B.1.617.2 vaccine candidate, induces potent humoral and Th1 cell response in mice and protects against B.1.617.2 strain challenge in Syrian hamsters.",2024,Arti Bharmoria,"Translational Health Science & Technology Institute (THSTI), NCR-Biotech Science Cluster, Faridabad, Haryana, India."
39911577,"CoviWall, a whole-virion-inactivated B.1.617.2 vaccine candidate, induces potent humoral and Th1 cell response in mice and protects against B.1.617.2 strain challenge in Syrian hamsters.",2024,Neeraj Rani,"Translational Health Science & Technology Institute (THSTI), NCR-Biotech Science Cluster, Faridabad, Haryana, India."
39911577,"CoviWall, a whole-virion-inactivated B.1.617.2 vaccine candidate, induces potent humoral and Th1 cell response in mice and protects against B.1.617.2 strain challenge in Syrian hamsters.",2024,Monika Lakhanpal,"Translational Health Science & Technology Institute (THSTI), NCR-Biotech Science Cluster, Faridabad, Haryana, India."
39911577,"CoviWall, a whole-virion-inactivated B.1.617.2 vaccine candidate, induces potent humoral and Th1 cell response in mice and protects against B.1.617.2 strain challenge in Syrian hamsters.",2024,C S Patil,"Translational Health Science & Technology Institute (THSTI), NCR-Biotech Science Cluster, Faridabad, Haryana, India."
39911577,"CoviWall, a whole-virion-inactivated B.1.617.2 vaccine candidate, induces potent humoral and Th1 cell response in mice and protects against B.1.617.2 strain challenge in Syrian hamsters.",2024,Nishan Singh,"Translational Health Science & Technology Institute (THSTI), NCR-Biotech Science Cluster, Faridabad, Haryana, India."
39911577,"CoviWall, a whole-virion-inactivated B.1.617.2 vaccine candidate, induces potent humoral and Th1 cell response in mice and protects against B.1.617.2 strain challenge in Syrian hamsters.",2024,Lovely Khan,"Translational Health Science & Technology Institute (THSTI), NCR-Biotech Science Cluster, Faridabad, Haryana, India."
39911577,"CoviWall, a whole-virion-inactivated B.1.617.2 vaccine candidate, induces potent humoral and Th1 cell response in mice and protects against B.1.617.2 strain challenge in Syrian hamsters.",2024,Lavit Jambu,"Translational Health Science & Technology Institute (THSTI), NCR-Biotech Science Cluster, Faridabad, Haryana, India."
39911577,"CoviWall, a whole-virion-inactivated B.1.617.2 vaccine candidate, induces potent humoral and Th1 cell response in mice and protects against B.1.617.2 strain challenge in Syrian hamsters.",2024,Naveen K Jain,"Translational Health Science & Technology Institute (THSTI), NCR-Biotech Science Cluster, Faridabad, Haryana, India."
39911577,"CoviWall, a whole-virion-inactivated B.1.617.2 vaccine candidate, induces potent humoral and Th1 cell response in mice and protects against B.1.617.2 strain challenge in Syrian hamsters.",2024,Syed Khalid Ali,"Translational Health Science & Technology Institute (THSTI), NCR-Biotech Science Cluster, Faridabad, Haryana, India."
39911577,"CoviWall, a whole-virion-inactivated B.1.617.2 vaccine candidate, induces potent humoral and Th1 cell response in mice and protects against B.1.617.2 strain challenge in Syrian hamsters.",2024,Priyanka Priyadarsiny,"Translational Health Science & Technology Institute (THSTI), NCR-Biotech Science Cluster, Faridabad, Haryana, India."
39911577,"CoviWall, a whole-virion-inactivated B.1.617.2 vaccine candidate, induces potent humoral and Th1 cell response in mice and protects against B.1.617.2 strain challenge in Syrian hamsters.",2024,Amulya K Panda,"Translational Health Science & Technology Institute (THSTI), NCR-Biotech Science Cluster, Faridabad, Haryana, India."
39911577,"CoviWall, a whole-virion-inactivated B.1.617.2 vaccine candidate, induces potent humoral and Th1 cell response in mice and protects against B.1.617.2 strain challenge in Syrian hamsters.",2024,Rajesh Jain,"Translational Health Science & Technology Institute (THSTI), NCR-Biotech Science Cluster, Faridabad, Haryana, India."
39911577,"CoviWall, a whole-virion-inactivated B.1.617.2 vaccine candidate, induces potent humoral and Th1 cell response in mice and protects against B.1.617.2 strain challenge in Syrian hamsters.",2024,Amit Awasthi,"Immuno-biology Lab, Centre for Immunobiology and Immunotherapy, Translational Health Science and Technology Institute, Near Capital Region (NCR)-Biotech Science Cluster, Faridabad, Haryana, India."
39911577,"CoviWall, a whole-virion-inactivated B.1.617.2 vaccine candidate, induces potent humoral and Th1 cell response in mice and protects against B.1.617.2 strain challenge in Syrian hamsters.",2024,Zaigham Abbas Rizvi,"Immuno-biology Lab, Centre for Immunobiology and Immunotherapy, Translational Health Science and Technology Institute, Near Capital Region (NCR)-Biotech Science Cluster, Faridabad, Haryana, India."
39906744,"A randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findings.",2024,Eric Holmgren,"BeiGene USA, Inc., San Mateo, CA, United States."
39906744,"A randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findings.",2024,Pil Kim,"BeiGene USA, Inc., San Mateo, CA, United States."
39906744,"A randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findings.",2024,Carrie Shi,"BeiGene USA, Inc., San Mateo, CA, United States."
39906744,"A randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findings.",2024,Holly Lin,"BeiGene USA, Inc., San Mateo, CA, United States."
39906744,"A randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findings.",2024,Vanitha Ramakrishnan,"BeiGene USA, Inc., San Mateo, CA, United States."
39906744,"A randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findings.",2024,Ying Ou,"BeiGene USA, Inc., San Mateo, CA, United States."
39906744,"A randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findings.",2024,Scott Olszewski,"BeiGene USA, Inc., San Mateo, CA, United States."
39906744,"A randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findings.",2024,Christopher Tankersley,"BeiGene USA, Inc., San Mateo, CA, United States."
39906744,"A randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findings.",2024,Todd Zimmerman,"BeiGene USA, Inc., San Mateo, CA, United States."
